Radiotherapy (RT) is one of the most important treatment options of cancer and also may activate the immune response. Because of this, we must discuss the question of "is the radiotherapy vaccine". If RT increases the immune response we must learn some more about the RT effects on the cells, cell surface antigene, immune checkpoints and their inhibition (ICI; CTLA4, PD1, PDL1 inhibition). It will be discussed the role of the radiotherapy and biologic effects of the radiotherapy to activate the immune response, radiotherapy dose, radiotherapy timing and the side effects of immune checkpoints inhibitors. Hypofractionated stereotactic body radiotherapy is widely used in clinical practice to achieve immune response, but with high conformal hypofractionated stereotactic radiotherapy the microenvironment around the cancer tissue such as fibroblast may survive and then may help cancer stem cells progression, and this is a very important subject should be taken into consideration in order to be better understood in future studies.

Êîìóíàëüíèé çàêëàä Õåðñîíñüêî¿ îáëàñíî¿ ðàäè «Õåðñîíñüêèé îáëàñíèé îíêîëîã³÷íèé äèñïàíñåð», Óêðà¿íàÌåòà: âèâ÷èòè ñòðóêòóðó õâîðèõ íà ðàê ìîëî÷íî¿ çàëîçè (ÐÌÇ) ç òåðì³íîì âèaeèâàííÿ ïîíàä ïÿòü ðîê³â. Ìàòåð³àëè ³ ìåòîäè. Ïðîâåäåíèé àíàë³ç õâîðèõ Õåðñîíñüêî¿ îáëàñò³ íà ÐÌÇ, ÿê³ ïåðåáóâàþòü íà îáë³êó ïÿòü ³ á³ëüøå ðîê³â.Ðåçóëüòàòè. Õâîð³ íà ÐÌÇ, ÿê³ aeèâóòü ïÿòü ³ á³ëüøå ðîê³â, ìàþòü ïåðåâàaeíî (92,7%) ² òà ²² ñòàä³þ çàõâîðþâàííÿ íà ìîìåíò âñòàíîâëåííÿ ä³àãíîçó. Çà ìîðôîëîã³÷íîþ áóäîâîþ â ñòðóêòóð³ õâîðèõ íà ÐÌÇ ïåðåâàaeàþòü (89,5%) çàëîçèñò³ ðàêè. 76,1% õâîðèõ íà ÐÌÇ, ÿê³ aeèâóòü ïÿòü ³ á³ëüøå ðîê³â, îòðèìàëè êîìá³íîâàíå òà êîìïëåêñíå ë³êóâàííÿ. Àíàë³ç ïîâ³êîâî¿ ñòðóêòóðè çàõâîðþâàíîñò³ íà ÐÌÇ ïîêàçàâ íàÿâí³ñòü äâîõ ï³ê³â çàõâîðþâàííîñò³: ó â³ö³ 4549 ðîê³â (18,5%) òà 5569 ðîê³â (32,3%).Âèñíîâêè. Âèñîêà âèaeèâàí³ñòü õâîðèõ ç ²-²² ñòàä³ÿìè çàõâîðþâàííÿ ï³äêðåñëþº âàaeëèâ³ñòü ðàííüî¿ ä³àãíîñòèêè ðàêó. Ç ìåòîþ âèÿâëåííÿ ÐÌÇ íà ðàíí³õ ñòàä³ÿõ ae³íêàì â³êîì 4569 ðîê³â íåîáõ³äíå ïðîâåäåííÿ ùîð³÷íîãî ìàìîãðàô³÷íîãî ñêðèí³íãó. Á³ëüøó âèaeèâàí³ñòü õâîðèõ íà ÐÌÇ çàáåçïå÷óº êîìïëåêñíå ³ êîìá³íîâàíå ë³êóâàííÿ.ÊËÞ×β ÑËÎÂÀ: ðàê ìîëî÷íî¿ çàëîçè, âèaeèâàí³ñòü.

No abstract